GlassScriptPhysician profile
Rafael Yakutilov
NPI 1003811720
$41,218.83
in general payments reported to CMS, 2019-2025
67 companies · $8,955 in 2025
The $8,955 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,014 · 2020: $2,771 · 2021: $5,012 · 2022: $6,660 · 2023: $6,644 · 2024: $8,162 · 2025: $8,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,310.52 |
| Education | $450.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,058.99 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $2,980.99 | 2021-2025 | Vraylar, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $2,474.55 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $1,980.97 | 2020-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $1,930.77 | 2019-2025 | Nuplazid |
| Ucb, INC. | $1,913.23 | 2020-2025 | Briviact, Nayzilam |
| Mallinckrodt Hospital Products INC. | $1,897.24 | 2020-2025 | Acthar |
| Biogen, INC. | $1,577.16 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Eisai INC. | $1,536.77 | 2019-2025 | |
| Harmony Biosciences LLC | $1,491.07 | 2022-2025 | Wakix |
| Neurelis, INC. | $1,376.14 | 2020-2025 | Valtoco |
| Amgen INC. | $1,235.59 | 2019-2025 | Krystexxa, Uplizna, Aimovig |
| Pfizer INC. | $1,182.13 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,005.65 | 2023-2025 | Rexulti, Nuedexta |
| Ani Pharmaceuticals, INC. | $902.75 | 2023-2025 | Purified Cortrophin Gel |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $844.17 | 2019-2022 | |
| Lundbeck LLC | $829.97 | 2019-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $743.05 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Novartis Pharmaceuticals Corporation | $693.90 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $693.15 | 2019-2022 | |
| Argenx US, INC. | $649.68 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $641.28 | 2022-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $572.59 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $528.30 | 2020-2025 | Firdapse |
| Axsome Therapeutics, INC. | $518.72 | 2023-2025 | Symbravo, Auvelity |
| E.R. Squibb & Sons, L.L.C. | $507.34 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $504.96 | 2023-2025 | |
| Celgene Corporation | $502.11 | 2021-2025 | Zeposia |
| Scilex Pharmaceuticals INC. | $460.67 | 2023-2025 | Ztlido |
| Vanda Pharmaceuticals INC. | $432.63 | 2022-2024 | Hetlioz, Fanapt |
| Grifols USA, LLC | $416.43 | 2020-2025 | Gamunex-C |
| Biohaven Pharmaceuticals, INC. | $397.85 | 2020-2021 | |
| Lilly USA, LLC | $378.00 | 2019-2025 | Reyvow, Emgality, Amyvid |
| Paratek Pharmaceuticals, INC. | $333.71 | 2021-2025 | Nuzyra |
| Arbor Pharmaceuticals, INC. | $328.23 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $321.71 | 2023-2024 | Aptiom |
| Mallinckrodt Enterprises LLC | $317.71 | 2019 | |
| Octapharma USA, INC. | $292.94 | 2024-2025 | Panzyga |
| Kyowa Kirin, INC. | $240.28 | 2023-2025 | Nourianz |
| Csl Behring | $232.15 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $198.01 | 2024-2025 | Hyqvia |
| Genzyme Corporation | $191.03 | 2019-2023 | |
| Impel Pharmaceuticals INC. | $178.13 | 2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $166.93 | 2023-2025 | Horizant, Horizant |
| Emd Serono, INC. | $161.92 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $156.13 | 2021-2022 | |
| Novo Nordisk INC | $123.88 | 2024 | Wegovy |
| Horizon Therapeutics Plc | $113.79 | 2021-2023 | Uplizna |
| Vertex Pharmaceuticals Incorporated | $113.43 | 2025 | |
| Redhill Biopharma INC. | $108.59 | 2020-2021 | |
| Genentech USA, INC. | $105.52 | 2020-2024 | Ocrevus, Ocrevus Zunovo |
| Jazz Pharmaceuticals INC. | $89.47 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $88.89 | 2025 | Inbrija, Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $87.77 | 2022 | |
| Almatica Pharma LLC | $86.15 | 2021-2022 | |
| Acorda Therapeutics, INC | $54.97 | 2019-2020 | |
| Smith+Nephew, INC. | $43.94 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $31.06 | 2019 | |
| Medtronic, INC. | $30.00 | 2021 | |
| Averitas Pharma INC. | $27.13 | 2023 | Qutenza |
| Livanova USA, INC. | $22.77 | 2021 | |
| Adamas Pharmaceuticals, INC. | $22.67 | 2021 | |
| Daiichi Sankyo INC. | $20.00 | 2019 | |
| Merck Sharp & Dohme LLC | $19.69 | 2021 | |
| Akcea Therapeutics, INC. | $18.97 | 2019 | |
| Corium, LLC | $18.75 | 2023 | Adlarity |
| Shionogi INC | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Yakutilov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.